Personalized dosimetry of 131I-rituximab radioimmunotherapy of lymphoma

被引：0
|
作者：
Boucek, J. A. [1 ]
Turner, J. [1 ]
机构：
[1] Univ Western Australia, Fremantle Hosp, Fremantle, WA, Australia
来源：
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2009年 / 36卷
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
引用
收藏
页码：S261 / S262
页数：2
相关论文
共 50 条
  • [41] Biodistribution and Dosimetry of Indigenously Produced 131I-Rituximab in B-Cell Lymphoma: Pilot Study Estimating Patient-Specific Dose Comparing 2 Different Dosimetric Methods
    Adnan, Aadil
    Deep, Kamal
    Kameswaran, Mythilli
    Nikam, Dilip
    Shanmukaih, Chandrakala
    Dash, Ashutosh
    Banerjee, Sharmila
    Basu, Sandip
    JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY, 2019, 47 (04) : 292 - 299
  • [42] Prognostic Significance of Pretreatment 18F-FDG PET/CT in Patients with Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma Treated by Radioimmunotherapy Using 131I-Rituximab
    Lim, Ilhan
    Park, Joon Yeun
    Kang, Hye Jin
    Hwang, Jae Pil
    Lee, Seung Sook
    Kim, Kyeong Min
    Choi, Tae Hyun
    Yang, Sung Hyun
    Kim, Byung Il
    Choi, Chang Woon
    Lim, Sang Moo
    ACTA HAEMATOLOGICA, 2013, 130 (02) : 74 - 82
  • [43] Biodistribution and individual dosimetry of I-131-labeled Rituximab in relapsed non-Hodgkin's lymphoma
    Scheidhauer, K
    Wolf, I
    von Schilling, C
    Schmidt, B
    Baumgartl, H
    Reidel, G
    Peschel, C
    Schwaiger, M
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE, 2001, 28 (08): : 981 - 981
  • [44] Repeated injections of 131I-rituximab show patient-specific stable biodistribution and tissue kinetics
    Antonescu, C
    Delaloye, AB
    Kosinski, M
    Monnin, P
    Schaffland, AO
    Ketterer, N
    Grannavel, C
    Kovacsovics, T
    Verdun, FR
    Buchegger, F
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2005, 32 (08) : 943 - 951
  • [45] LONG-TERM OUTCOMES OF 131I-RITUXIMAB RADIOIMMUNOTHERAPY IN FOLLICULAR NON-HODGKIN LYMPHOMA: TEN YEAR UPDATE ON TOXICITY, TIME-TO-NEXT-TREATMENT AND SURVIVIAL OF THE PHASE II INITIAL STUDY
    Kesavan, M.
    Turner, J. H.
    McQuillan, A. D.
    HAEMATOLOGICA, 2016, 101 : 274 - 275
  • [46] 131I-rituximab治疗B细胞非霍奇金淋巴瘤
    蔡秋琼
    杜明华
    国际放射医学核医学杂志, 2008, (02)
  • [47] Radiation dosimetry results for Zevalin radioimmunotherapy of rituximab-refractory non-Hodgkin lymphoma
    Wiseman, GA
    Leigh, B
    Erwin, WD
    Lamonica, D
    Kornmehl, E
    Spies, SM
    Silverman, DHS
    Witzig, TE
    Sparks, RB
    White, CA
    CANCER, 2002, 94 (04) : 1349 - 1357
  • [48] A pioneer experience in Malaysia on In-house Radio-labelling of 131I-rituximab in the treatment of Non-Hodgkin's Lymphoma and a case report of high dose 131I-rituximab-BEAM conditioning autologous transplant
    Kuan, Jew Win
    Law, Chiong Soon
    Wong, Xiang Qi
    Ko, Ching Tiong
    Awang, Zool Hilmi
    Chew, Lee Ping
    Chang, Kian Meng
    APPLIED RADIATION AND ISOTOPES, 2016, 116 : 13 - 21
  • [49] First-Line Radio-Immunotherapy of Newly Diagnosed, Advanced Follicular Non-Hodgkin Lymphoma with 131I-Rituximab: The INITIAL Study
    McQuillan, Andrew D.
    Macdonald, William B. G.
    Leahy, Michael F.
    Turner, J. Harvey
    BLOOD, 2011, 118 (21) : 1589 - 1589
  • [50] Repeated injections of 131I-rituximab show patient-specific stable biodistribution and tissue kinetics
    Cristian Antonescu
    Angelika Bischof Delaloye
    Marek Kosinski
    Pascal Monnin
    Andreas O. Schaffland
    Nicolas Ketterer
    Carine Grannavel
    Tibor Kovacsovics
    Francis R. Verdun
    Franz Buchegger
    European Journal of Nuclear Medicine and Molecular Imaging, 2005, 32 : 943 - 951
12345